Chemokine-receptor profiling for painful diabetic neuropathy in biological samples from human clinical trials
Chemokine-receptor profiling for painful diabetic neuropathy in biological samples from human clinical trials
批准号:
10326651
负责人:
Thomas P Richardson
金额:
$70.01万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-20 至 2023-12-15
关键词:
AffectAlternative SplicingAmino Acid SequenceApplications GrantsAreaAttenuatedBiologicalBiological AssayC-terminalClinicClinicalClinical DataClinical TrialsClinical Trials DesignComplexDataDevelopmentDiabetes MellitusDiabetic NeuralgiaDiagnostic Reagent KitsDrug AntagonismDrug IndustryGeneticHealthcareHeart DiseasesHumanIndividualInflammationInflammatoryInvestigational DrugsInvestmentsJournalsKnock-outLaboratoriesLeadLigandsMalignant NeoplasmsMeasuresMedicalMessenger RNAMethodsMolecularNeuropathyNociceptionOutcomePainPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhasePhase II Clinical TrialsPhenotypePhysiciansPlayPopulation HeterogeneityProcessProduct LabelingProtein IsoformsPublishingQuality of lifeReceptor GeneRoleSamplingSerumSignal TransductionSmall Business Innovation Research GrantSourceSystemTherapeuticTransgenic MiceTreatment outcomeWorkbasechemokinechemokine receptorchronic painchronic painful conditionclinical developmentclinical diagnosticscompanion diagnosticsdiabetic patientdrug developmenteconomic costfollow-upgenetic profilingin-vitro diagnosticsinclusion criteriamRNA Precursormaterial transfer agreementmonocyte chemoattractant protein 1 receptorneuroinflammationpain patientpain reductionpain reliefpainful neuropathypatient populationpatient responsepatient stratificationphase 1 studyphase 2 studyphase II trialpopulation basedprimary endpointprogramsreceptorreceptor expressionresearch clinical testingresponders and non-respondersresponsesecondary endpointsuccesstherapeutic targettool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Chronic pain is a major healthcare burden, representing economic costs of up to $635B per year, more
than cancer, diabetes, and heart disease, according to a Johns Hopkins study published in the Journal of Pain.
Pain is a highly heterogeneous condition comprising neuropathic, nociceptive and inflammatory components,
and patient responses to currently available drugs vary greatly.
A very promising approach to target various forms of pain is through antagonism of key players in neuro-
inflammation. Specifically, the chemokine receptor system, a complex network of over 20 different receptors and
over 80 ligands, is integral to neuroinflammatory processes and the pharmaceutical industry had been very active
in developing compounds targeting individual receptors in the network. However, the biological complexity,
ligand promiscuity, and receptor redundancy of the chemokine receptor system has precluded successful clinical
development of the compounds and many pharma have exited the pain therapeutic area.
A major limitation of successful targeting of this network is sufficient understanding of the molecular and
cellular dynamics of the chemokine network, and how specific receptors vary in chronic pain conditions. In this
study, we aim to determine the genetic expression of a chemokine receptor utilizing human clinical samples
collected in a clinical trial evaluating a receptor antagonist. Further, we will utilize this understanding in
conjunction with patient efficacy data from the clinical trials to continue the development of our lead compound,
a drug that showed a statistically significant clinical signal in pain. Results from this study will enable patient
stratification and effective clinical trial design by including patients with the appropriate genetic and phenotypic
background and thus significantly increase the likelihood achieving primary endpoints of pain reduction in the
clinic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金